本帖最后由 老马 于 2012-1-13 21:20 编辑 5 N$ {& g" Y1 C# H
) d* k6 S E7 J- R* E4 R: U6 T
爱必妥和阿瓦斯丁的比较5 p$ i8 O' @: k7 c
) ?, e1 g3 g( _
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/' p. u& q6 w- [1 a
9 V/ N8 [& n/ V% q1 n/ p) N
$ e0 O0 t3 R& K+ T# {" D2 B4 `http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
+ [* F0 T& i! J8 [================================================== o1 U1 [: U" a* D5 a4 M0 j
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)0 P+ ?! o7 N+ k
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. S, s4 i) J1 t' X( u
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.7 H( }) r1 x, i( f$ i
|
11011102001537 )
显身卡
+ r! P& v+ u- O# u1 j
